ABSTRACT
Paralytic ileus is a temporary arrest of intestinal peristalsis. We report on two patients with breast cancer who developed paralytic ileus following treatment with capecitabine. The pathophysiology of this disorder and its possible connection to capecitabine are described with the aim of promoting the early recognition of the clinical picture so that unnecessary surgery can be avoided.
Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Breast Neoplasms/drug therapy , Deoxycytidine/analogs & derivatives , Fluorouracil/analogs & derivatives , Intestinal Pseudo-Obstruction/chemically induced , Aged , Antimetabolites, Antineoplastic/administration & dosage , Capecitabine , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Female , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Humans , Intestinal Pseudo-Obstruction/physiopathology , Middle AgedSubject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Chemotherapy, Adjuvant , Estrogens , Neoplasms, Hormone-Dependent/drug therapy , Nitriles/therapeutic use , Progesterone , Tamoxifen/therapeutic use , Triazoles/therapeutic use , Aged , Antineoplastic Agents, Hormonal/adverse effects , Aromatase Inhibitors , Breast Neoplasms/therapy , Disease-Free Survival , Enzyme Inhibitors/adverse effects , Enzyme Inhibitors/therapeutic use , Female , Fractures, Bone/epidemiology , Fractures, Bone/etiology , Humans , Letrozole , Lipids/blood , Middle Aged , Neoplasm Proteins/antagonists & inhibitors , Neoplasms, Hormone-Dependent/therapy , Nitriles/adverse effects , Osteoporosis, Postmenopausal/chemically induced , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/prevention & control , Postmenopause , Quality of Life , Triazoles/adverse effectsABSTRACT
Interleukin-6 (IL-6) is the major growth and survival factor for multiple myeloma (MM), and has been shown to protect MM cells from apoptosis induced by a variety of agents. IL-6 receptor antagonists, which prevent the assembly of functional IL-6 receptor complexes, inhibit cell proliferation and induce apoptosis in MM cells. We have investigated whether the IL-6 receptor super-antagonist Sant7 might enhance the antiproliferative and apoptotic effects induced by the combination of dexamethasone (Dex) and zoledronic acid (Zln) on human MM cell lines and primary cells from MM patients. Here we show that each of these compounds individually induced detectable antiproliferative effects on MM cells. Sant7 significantly enhanced growth inhibition and apoptosis induced by Dex and Zln on both MM cell lines and primary MM cells. These results indicate that overcoming IL-6 mediated cell resistance by Sant7 potentiates the effect of glucocorticoides and bisphosphonates on MM cell growth and survival, providing a rationale for therapies including IL-6 antagonists in MM.
